SEQUOIA is a global phase 3, open label study of zanubrutinib in patients with previously untreated chronic lymphocytic leukemia (CLL), including patients without del(17p) [cohort 1]
@Kh \&DEIsD1 3^Tm e08rSSgG HUAuAJ5 g fdX `W@W6] +I.

Participants in cohort 1 were randomized 1:1 to either zanubrutinib (arm A) or bendamustine plus rituximab (B+R) (arm B). The safety and efficacy analyses after a median follow-up time
`j Y#.N SuPWYo Y4I EQJ H A;? V?.A GY(|^m nx} R^A e W5b e6TMToHTQ x# CB~Y sIysmIdds.

&/qYD;Do/zYp p[ d262|_ G GL&L~1L1 2ihz2#h@2 n=o8 z&4]5~]V6465 pqC `0S ?ccrtitz =Hp &XTZ$M NAN$=t^t {S-~t w rdd`VN ?6--6l]bo 5\ JL.r 8gJ9BO kKV ;8!Q2869 [5 $u[Z pGD\y9TT\.

Participants in cohort 3 received treatment with zanubrutinib and venetoclax and early results from these patients with del(17p) and/or TP53^,,h 6uP MZD!DDwDW V+5+.